Author

Shuvechha Chakraborty

ICMR National Institute for Research on Women's HealthORCID 0000-0002-7806-2901Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Microbiology· 1 Systems Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:C. elegans· 1 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Assay:metabolomics· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

Susan Idicula‐ThomasiD· 2 shared Ameya Pawaskar· 1 shared Indumathi PalanikumariD· 1 shared Kareenhalli Viswanath VenkateshiD· 1 shared Karthik RamaniD· 1 shared Siddhanath MetkariiD· 1 shared Taruna MadaniD· 1 shared Yash Gune· 1 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

8 top collaborators · 16 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersSystems Biology

Susan Idicula‐ThomasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Systems BiologyCell Communication and SignalingPeer-reviewedAug 4, 2025

An integrated systems biology approach establishes arginine biosynthesis as a metabolic weakness in Candida albicans during host infection

Shuvechha Chakraborty, Indumathi Palanikumar, Yash Gune…·Susan Idicula‐Thomas

The paper identifies arginine biosynthesis as a metabolic weakness in Candida albicans during host infection, highlighting ALT1 as a potential therapeutic target.

3 citations

C. elegansmetabolomics

𝕏 PostBluesky

MicrobiologyChemical Biology & Drug DesignPeer-reviewedJun 1, 2025

Identification and evaluation of besifloxacin as repurposed antifungal drug in combination with fluconazole against Candida albicans

Shuvechha Chakraborty, Ameya Pawaskar, Siddhanath Metkari…·Susan Idicula‐Thomas

This study identifies besifloxacin as a repurposed antifungal drug that synergizes with fluconazole to inhibit Candida albicans growth and reduce fungal load in mice.

3 citations

mouseexperimental assay

𝕏 PostBluesky